Combination Therapy for Transitional Cell, Carcinoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Transitional Cell, Carcinoma+12 More
BA3071 - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The objective of this study is to assess safety and efficacy of BA3071 in solid tumors

Eligible Conditions
  • Transitional Cell, Carcinoma
  • Malignant Neoplasm of Stomach
  • Liver carcinoma
  • Melanoma
  • Solid Tumors, Adult
  • Renal Cell Carcinoma
  • Small Cell Lung Cancer (SCLC)
  • Non-Small Cell Lung Carcinoma (NSCLC)
  • Cervical Carcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Transitional Cell, Carcinoma

Study Objectives

4 Primary · 11 Secondary · Reporting Duration: Up to 24 months

Up to 24 months
Area under the plasma concentration versus time curve (AUC)
Assess dose limiting toxicity as defined in the protocol
Assess maximum tolerated dose as defined in the protocol
Confirmed best overall response (BOR)
Confirmed overall response rate (ORR)
Confirmed overall response rate (ORR) per RECIST v1.1
Disease control rate (DCR)
Duration of response (DOR)
Frequency and severity of AEs and/or SAEs
Overall survival (OS)
Peak Plasma Concentration (Cmax)
Percent change from baseline in target lesion sum of diameters.
Phase 1: Pharmacokinetics
Progression-free survival (PFS)
Time to response (TTR)

Trial Safety

Safety Progress

1 of 3

Other trials for Transitional Cell, Carcinoma

Trial Design

2 Treatment Groups

Combination Therapy
1 of 2
BA3071
1 of 2
Experimental Treatment

36 Total Participants · 2 Treatment Groups

Primary Treatment: Combination Therapy · No Placebo Group · Phase 1 & 2

Combination TherapyExperimental Group · 2 Interventions: BA3071, Nivolumab · Intervention Types: Biological, Biological
BA3071
Biological
Experimental Group · 1 Intervention: BA3071 · Intervention Types: Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nivolumab
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 24 months

Who is running the clinical trial?

BioAtla, Inc.Lead Sponsor
5 Previous Clinical Trials
880 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: October 30th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.